Pull to refresh
Logo
Daily Brief
Following Why Sign Up
MIT creates injectable mini livers that work inside the body

MIT creates injectable mini livers that work inside the body

New Capabilities

Liver cells delivered with hydrogel microspheres stayed viable in mice for eight weeks, offering a transplant-free path for liver failure.

5 days ago: ScienceDaily recirculates the satellite-liver findings

Overview

Updated 4 days ago

More than 10,000 Americans with chronic liver disease wait for a transplant, and many are too sick for the surgery. MIT engineers have developed an injectable alternative: liver cells bundled with hydrogel microspheres that settle into the body and form working tissue.

In mice, the injected cells stayed alive and secreted liver proteins for eight weeks, the full length of the study. The approach, published in Cell Biomaterials, could serve as a bridge for patients awaiting a donor organ — or eventually replace transplant surgery for some.

Why it matters

Liver patients too sick for transplant surgery could gain an injectable treatment instead of waiting for a donor organ.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

10,000+
Americans on the liver transplant waitlist
More than 10,000 people wait, and many are not healthy enough for surgery.
8 weeks
Injected liver cells stay viable in mice
Cells produced liver-specific proteins for the entire length of the study.
3
Components in the injectable mixture
Hepatocytes, hydrogel microspheres, and supportive fibroblast cells.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Sangeeta Bhatia
Sangeeta Bhatia
John and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science, MIT; senior author of the study
Leading the research behind the injectable liver-cell therapy
VK
Vardhman Kumar
Postdoctoral researcher at MIT's Koch Institute; lead author of the study
Led development of the hydrogel microsphere injection technique
 Nicole Henning
Nicole Henning
Ultrasound research specialist, Koch Institute
Developed the ultrasound-guided injection and monitoring protocol

Organizations Involved

MIT Koch Institute for Integrative Cancer Research
MIT Koch Institute for Integrative Cancer Research
Research institute at MIT
Host laboratory for the injectable liver-cell research

MIT's interdisciplinary cancer research center where the injectable liver-cell therapy was developed.
MIT Institute for Medical Engineering and Science
MIT Institute for Medical Engineering and Science
Academic institute at MIT
Affiliated research home for the study's senior author

Cross-disciplinary MIT institute working at the intersection of engineering and medicine, where Bhatia holds an appointment.

Timeline

March 2026 September 2026

3 events Latest: 5 days ago

  1. ScienceDaily recirculates the satellite-liver findings

    Latest Media coverage

    ScienceDaily republished the MIT research announcement, widening public awareness of the experimental therapy.

  2. Technology Review features the liver-cell research

    Media coverage

    MIT Technology Review published a feature on the injectable mini livers and their potential as a transplant alternative.

  3. MIT announces injectable satellite livers

    Research publication

    MIT News released the Cell Biomaterials study showing injected liver cells stayed functional in mice for eight weeks.

Scenarios

1

Phase 1 human trial begins within three years

Unlikely Resolves by Sep 7, 2029

Discussed by: The research team, which says further studies are needed before human testing

The therapy clears remaining hurdles — longer safety data, scalable cell sourcing, and immune compatibility — and the group registers a first-in-human trial. Given typical cell-therapy timelines, this would require a fast regulatory and manufacturing path.

2

Long-term animal studies prove durable function

Likely Resolves by Sep 7, 2027

Discussed by: The MIT team's stated next steps

The group runs longer animal studies showing cells function well beyond eight weeks, with safety data, before any human trial. This is the natural next milestone for the technology.

3

Spinout company formed to commercialize the therapy

Possible Resolves by Sep 7, 2028

Discussed by: Pattern of prior commercialization from Bhatia's lab

The technology is licensed to or spun into a company to fund clinical development, a common step for MIT biomedical technologies. Bhatia has founded companies from her lab's work before, making this a plausible route to translation.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

July 2000

Edmonton Protocol (2000)

Researchers at the University of Alberta transplanted pancreatic islet cells from donor organs into seven patients with severe type 1 diabetes. All seven stopped needing insulin injections for at least a year.

Then

The protocol proved that cellular therapy could restore organ function without a whole-organ transplant. But patients faced lifelong immunosuppression, and islet function often faded within a few years.

Now

Islet transplantation became a standard option for selected patients, yet donor supply and immune rejection kept it from wide use.

Why this matters now

The MIT satellite-liver approach faces the same twin hurdles — immunosuppression and long-term cell survival — that limited the Edmonton Protocol.

2014–2020s

Encapsulated beta cell therapy (2014–2020s)

Companies like ViaCyte tested device-encapsulated, stem-cell-derived beta cells for diabetes, aiming to let transplanted cells work without immunosuppression. Early trials showed cells survived and produced insulin, but efficacy was modest.

Then

Encapsulation protected cells from immune attack in some patients, a proof of concept for shielding donor cells.

Now

The field has continued refining encapsulation, with mixed clinical results so far.

Why this matters now

The MIT team's 'stealthy hepatocytes' and immunosuppressant-eluting microspheres are direct attempts to solve the same immune-compatibility problem.

1990s–2000s

Hepatocyte transplantation trials (1990s–2000s)

Doctors infused donor liver cells directly into patients with metabolic liver disease as an alternative to whole-organ transplant. Some patients showed temporary improvement in liver function.

Then

Most grafts failed to engraft durably; cells survived poorly and were often rejected.

Now

The approach never reached broad clinical use, limited by cell survival, engraftment, and donor scarcity.

Why this matters now

The MIT microsphere niche directly targets the engraftment failure that stalled earlier hepatocyte transplants.

Sources

(10)
+4
MIT News ScienceDaily EurekAlert! MIT Technology Review Newsweek MIT EECS MIT Institute for Medical Engineering and Science Harvard-MIT Health Sciences and Technology BioTechniques GreenWatchBD